Vanda Pharmaceuticals (VNDA) 10-K2009 FY Annual report

Filed: 15 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accident, activist, acute, advisor, agenda, alleging, ample, antitrust, augment, blind, bring, bringing, broad, Canada, capacity, clarification, constrain, contest, damage, deferral, deliverable, delivery, diligence, disaggregation, disclaim, doubtful, dramatic, element, eligible, enhance, exacerbate, exact, faith, false, Fanapttm, fewer, fraud, fraudulent, hope, Hour, imposition, inventory, Joint, JSC, knowingly, landscape, length, lengthy, lost, Medicaid, mentioned, merge, misuse, noncompliance, nonrecurring, novelty, objective, orphan, oversee, path, pediatric, perception, persuasive, PLR, preclinical, preliminarily, PTO, recommend, reconciliation, registry, relinquished, Relprevytm, resolution, rollforward, RSU, scrutiny, shut, shutdown, Statute, Steering, straight, strive, Sustennatm, taxpayer, thirteen, tightening, trademark, training, undefined, uneconomical, unforeseeable, unintended, unsuccessful, vendor, voluntarily, waged, waiver, write

Removed: abatement, abide, abnormal, accounted, Adjustable, akathisia, allocated, amendment, antipsychotic, APB, attribute, avoid, blood, bodily, breast, budgeting, build, bulletin, cancelled, captured, CATIE, closed, cognition, comprising, conducting, confirmed, Contingently, corrected, correlation, death, deficit, defray, discontinuation, discontinued, dissatisfaction, dose, EITF, electrical, electrocardiogram, elevated, employ, England, enjoy, enterprise, enthusiastically, exceeded, exceeding, excessive, expiring, extinguished, extrapyramidal, fainting, FIN, Finally, forma, found, function, funded, gene, globally, granting, heart, hyperprolactinemia, identified, impacted, impossible, IMS, incidence, incorrect, induction, injected, instance, intermediate, interpretation, interpreted, interval, Interventional, inThe, invested, involuntary, IssueNo, Journal, July, larger, linked, LLC, managerial, managing, medication, men, mid, milk, moderate, modest, molecule, mutation, note, noted, occasional, operational, pharmacogenetic, pipeline, placement, planning, prescribing, pro, prolactin, prolongation, prolonged, QTc, regimen, renewable, rent, SAB, secretion, simplified, sit, somnolence, Supplementary, threshold, titration, uncommon, understood, usingEITF, vacated, variable, women

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VNDA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION

PURSUANT TO RULE 13A – 14(B) OF THE OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350

In connection with the Annual Report of Vanda Pharmaceuticals Inc. (the “Registrant”) on Form 10-K for the annual period ended December 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mihael H. Polymeropoulos, certify, in accordance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that to the best of my knowledge:

	(1)		The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934; and

	(2)		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.



Date: March 15, 2010	/s/ Mihael H. Polymeropoulos
	Mihael H. Polymeropoulos
	President and Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.